Status:
NOT_YET_RECRUITING
Determining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Conditions:
Basal Cell Carcinoma of Skin, Site Unspecified
Epidermoid Carcinoma
Eligibility:
All Genders
Phase:
NA
Brief Summary
The main aim of this study is to determine the prevalence of Muir-Torre syndrome (MTS) in the population of patients with Lynch syndrome (LS) confirmed by genetic analysis. Other aims include describi...
Detailed Description
Muir-Torre Syndrome (MTS) is an autosomal dominant disease described independently by Muir et al. in 1967 and Torre in 1968, defined by the association of a visceral tumor of the Lynch spectrum (color...
Eligibility Criteria
Inclusion
- Patient with a germline alteration of one of the MMR (MisMatch Repair) pathway genes (MLH1, PMS2, MSH2, MSH6) proven by constitutional genetic analysis (genetically authenticated Lynch syndrome).
- Patient followed at Nîmes University Hospital.
- Patient having given free and informed consent.
- Person affiliated to or benefiting from a social security scheme.
Exclusion
- Person under court protection, guardianship or curatorship.
- A person who is unable to give consent.
- Person for whom it is impossible to give informed information.
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT07201012
Start Date
December 1 2025
End Date
December 1 2027
Last Update
November 17 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.